SBIR Phase II: Machine Learning for Rapid Automated Viral Infectivity Assays (COVID-19) — NSF Award to ViQi LLC (CA, $1,696,774)
The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to accelerate the development of antiviral drugs and vaccines for conditions such as COVID-19. The ability to accurately determine if cells are infected with virus is crucial for evaluating antiviral drugs and vaccine candidates. C
| Award title | SBIR Phase II: Machine Learning for Rapid Automated Viral Infectivity Assays (COVID-19) |
|---|---|
| Award ID | 2136850 |
| Awardee | ViQi LLC |
| City | SANTA BARBARA |
| State | CA |
| Amount obligated | $1,696,774 |
| Principal investigator | Christian Lang |
| Program | SBIR Phase II |
| Start date | 04/01/2022 |
| Abstract | The broader impact of this Small Business Innovation Research (SBIR) Phase II project is to accelerate the development of antiviral drugs and vaccines for conditions such as COVID-19. The ability to accurately determine if cells are infected with virus is crucial for evaluating antiviral drugs and vaccine candidates. Currently, determining if a virus is infectious is done by infecting cells and waiting for them to die, which can take many days. The proposed technology uses artificial intelligenc |
| Source | NSF Awards |
$799/mo
Try NSFGrants →